John Fenley
Psychiatry · Johnson City, TNNPI 1568537751
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,119,425 of the $1,370,446 with a category attached, or 81.7%. 27 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 34.9% of the total. 2025 is the largest year on record at $316,484, 2.3 times the $139,468 reported in 2019. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,598 payments — averaging $527.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$479K
- Otsuka America Pharmaceutical, Inc.$423K
- Axsome Therapeutics, Inc.$223K
- AbbVie$210K
- Alkermes, Inc.$19K
- Sunovion Pharmaceuticals Inc.$8K
- plus $9K from 21 others
What the payments were for
- Consulting fees$107,8908%
- Speaking & faculty fees$1,119,42582%
- Travel & lodging$106,9118%
- Food & beverage$35,9393%
- Education$2810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 627 | $478,827 |
| Otsuka America Pharmaceutical, Inc. | 554 | $423,204 |
| Axsome Therapeutics, Inc. | 324 | $223,099 |
| AbbVie(2 entities) | 484 | $209,896 |
| Alkermes, Inc. | 68 | $18,778 |
| Sunovion Pharmaceuticals Inc. | 155 | $7,869 |
| Takeda Pharmaceuticals U.S.A., Inc. | 77 | $3,059 |
| Neurocrine Biosciences, Inc. | 57 | $1,047 |
| Vanda Pharmaceuticals Inc. | 53 | $917 |
| Teva Pharmaceuticals USA, Inc. | 36 | $825 |
| Lundbeck LLC | 31 | $515 |
| Bausch Health US, LLC | 28 | $504 |
| Idorsia Pharmaceuticals US Inc | 28 | $468 |
| Johnson & Johnson | 27 | $458 |
| Supernus Pharmaceuticals, Inc. | 8 | $190 |
| Merck | 8 | $126 |
| Tris Pharma Inc | 6 | $124 |
| Eisai Inc. | 7 | $110 |
| E.r. Squibb & Sons, L.L.C. | 5 | $107 |
| Acadia Pharmaceuticals Inc | 1 | $97 |
| Almatica Pharma LLC | 4 | $72 |
| Jazz Pharmaceuticals Inc. | 4 | $64 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,370,446 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 38 | $331,918 |
| CaplytaLumateperone Tosylate | 111 | $181,678 |
| AuvelityDextromethorphan Hbr/Bupropion | 83 | $95,475 |
| VraylarCariprazine Hcl | 49 | $71,542 |
| LatudaLurasidone Hcl | 12 | $34,228 |
| RexultiBrexpiprazole | 13 | $24,131 |
| Wellbutrin SrBupropion Hcl | 12 | $20,035 |
| Lurasidone Hcl | 134 | $19,049 |
| TrintellixVortioxetine Hydrobromide | 23 | $17,625 |
| Effexor XrVenlafaxine Hcl | 12 | $12,995 |
| DayvigoLemborexant | 22 | $7,624 |
| CymbaltaDuloxetine Hcl | 14 | $6,478 |
| Quetiapine Fumarate | 241 | $5,914 |
| Vilazodone Hcl | 41 | $5,119 |
| Armodafinil | 93 | $4,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,047 | $331,91838 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $478,827 | $181,678111 claims |
| Axsome Therapeutics, Inc.Auvelity | $223,099 | $95,47583 claims |
| AbbVieVraylar | $209,896 | $71,54249 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $7,869 | $34,22812 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $423,204 | $24,13113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $3,059 | $21,87135 claims |
| Eisai Inc.Dayvigo | $110 | $7,62422 claims |
| Almatica Pharma LLCSertraline Hcl | $72 | $1,320164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Johnson City
- Brian BonfardinJohnson City$2.6M
- George BrownJohnson City$91K
- Kevin TurnerJohnson City$9K
- Rakesh AminNashville$3M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.